These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3354400)

  • 1. Short-term infarct vessel patency with aspirin and dipyridamole started 24 to 36 hours after intravenous streptokinase.
    Hays LJ; Beller GA; Moore CA; Burwell LR; Craddock GB; Gascho JA; Smucker ML; Tedesco C; Nygaard TW
    Am Heart J; 1988 Apr; 115(4):717-21. PubMed ID: 3354400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.
    Théroux P; Pérez-Villa F; Waters D; Lespérance J; Shabani F; Bonan R
    Circulation; 1995 Apr; 91(8):2132-9. PubMed ID: 7697841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
    Thompson PL; Aylward PE; Federman J; Giles RW; Harris PJ; Hodge RL; Nelson GI; Thomson A; Tonkin AM; Walsh WF
    Circulation; 1991 May; 83(5):1534-42. PubMed ID: 1902404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin and infarct coronary artery patency after streptokinase in acute myocardial infarction.
    Mahan EF; Chandler JW; Rogers WJ; Nath HR; Smith LR; Whitlow PL; Hood WP; Reeves RC; Baxley WA
    Am J Cardiol; 1990 Apr; 65(15):967-72. PubMed ID: 2327357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial.
    Hillis LD; Borer J; Braunwald E; Chesebro JH; Cohen LS; Dalen J; Dodge HT; Francis CK; Knatterud G; Ludbrook P
    J Am Coll Cardiol; 1985 Nov; 6(5):957-62. PubMed ID: 4045046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.
    White HD; Aylward PE; Frey MJ; Adgey AA; Nair R; Hillis WS; Shalev Y; Brown MA; French JK; Collins R; Maraganore J; Adelman B
    Circulation; 1997 Oct; 96(7):2155-61. PubMed ID: 9337184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated infusion of streptokinase in acute myocardial infarction results in better TIMI flow grade in infarct-related artery.
    Dwivedi SK; Saran RK; Narain VS; Bansal S; Gupta R; Puri VK
    Indian Heart J; 2000; 52(1):40-4. PubMed ID: 10820932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
    Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
    Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.
    Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM
    Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators
    N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty.
    Bruna C; Rossetti G; Vado A; Racca E; Steffenino G; Dellavalle A; Ribichini F; Ferrero V; Menardi E; Uslenghi E
    G Ital Cardiol; 1998 Jan; 28(1):3-11. PubMed ID: 9493040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis).
    Peters RJ; Spickler W; Théroux P; White H; Gibson M; Molhoek PG; Anderson HV; Weitz JI; Hirsh J; Weaver WD
    Am Heart J; 2001 Aug; 142(2):237-43. PubMed ID: 11479461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Independent impact of thrombolytic therapy and vessel patency on left ventricular dilation after myocardial infarction. Serial echocardiographic follow-up.
    Popović AD; Nesković AN; Babić R; Obradović V; Bozinović L; Marinković J; Lee JC; Tan M; Thomas JD
    Circulation; 1994 Aug; 90(2):800-7. PubMed ID: 8044951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose intravenous streptokinase in acute myocardial infarction--short and long term prognosis.
    MacLennan BA; McMaster A; Webb SW; Khan MM; Adgey AA
    Br Heart J; 1986 Mar; 55(3):231-9. PubMed ID: 3954907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
    Hsia J; Kleiman N; Aguirre F; Chaitman BR; Roberts R; Ross AM
    J Am Coll Cardiol; 1992 Jul; 20(1):31-5. PubMed ID: 1607535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Systemic thrombolysis with short-term streptokinase infusion in acute myocardial infarct].
    Schröder R; Biamino G; von Leitner ER; Linderer T; Heitz J; Vöhringer HF; Wegscheider K; Andresen D; Arntz HR; Brüggemann T; Grassot A; Lichey J; Oeff M; Prokein E; Schäfer JH; Sörensen R
    Z Kardiol; 1982 Nov; 71(11):709-18. PubMed ID: 7157926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial.
    Brouwer MA; van den Bergh PJ; Aengevaeren WR; Veen G; Luijten HE; Hertzberger DP; van Boven AJ; Vromans RP; Uijen GJ; Verheugt FW
    Circulation; 2002 Aug; 106(6):659-65. PubMed ID: 12163424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin does not improve early arterial patency after streptokinase treatment for acute myocardial infarction.
    Norris RM; White HD; Cross DB; Woo KS; Maslowski AH; Caruana MP; Hart HH; Williams B
    Br Heart J; 1993 Jun; 69(6):492-5. PubMed ID: 8343314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thallium-dipyridamole in acute myocardial infarction treated by thrombolysis: diagnostic and prognostic value].
    D'Urbano M; Cafiero F; Cammelli F; Spreafico GL; Romano S
    G Ital Cardiol; 1994 Jan; 24(1):11-20. PubMed ID: 8200491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction.
    Cherng WJ; Chiang CW; Kuo CT; Lee CP; Lee YS
    Am Heart J; 1992 Apr; 123(4 Pt 1):841-6. PubMed ID: 1549990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.